Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes
World Journal of Diabetes · 2026-11-15 · 17 (11)
DOI: 10.4239/wjd.123922 ↗Abstract
BACKGROUND Diverse anti-diabetic combinations are widely indicated for uncontrolled hyperglycemia to avoid microvascular complications including kidney injury. Current studies on combination therapy’s long-term renal risk yield conflicting results, largely limited by inadequate confounder adjustment. We hypothesized combination anti-diabetic therapy reduces major adverse kidney events (MAKE) vs monotherapy in diabetic patients. AIM To investigate the association between the diversity of anti-diabetic therapy and long-term renal outcomes in patients with diabetes. METHODS We included participants with diabetes and glycated hemoglobin A1c ≥ 7% from the UK Biobank (UKB) and Chongqing Diabetes Registry (CDR). Using a target trial emulation design, we compared the effect of monotherapy vs combination therapy on MAKE (composite of end-stage renal disease and kidney disease death). Intention-to-treat and per-protocol analyses were conducted in UKB and CDR, respectively. RESULTS Propensity score matching identified 3475 monotherapy-combination therapy pairs in the UKB and 261-808 pairs in the CDR. Over median 13.4 years in UKB, combination therapy was associated with lower MAKE risk vs monotherapy (hazard ratio 0.65; 95% confidence interval: 0.46-0.92). In CDR, when compared with patients who maintained monotherapy, patients who maintained combination therapy had significantly lower risk of MAKE (hazard ratio 0.24; 95% confidence interval: 0.11-0.55) although their glycated hemoglobin A1c level was similar at baseline and during follow up. Sensitivity analyses excluding renoprotective medications showed consistent results. CONCLUSION Beyond glycemic control, a greater diversity of anti-diabetic therapy is associated with lower risk of MAKE in diabetic patients.
EUVIMED